Article Sidebar

Submitted
November 12, 2019
Accepted
August 31, 2020
Published
August 31, 2020
Download
PDF
Statistic
Read Counter : 697 Download : 722

Main Article Content

Abstract

Adjuvant chemotherapy has been widely applied in patients with breast malignancy after surgery to prevent its recurrence and to improve survival comprehensively. Febrile neutropenia is one of the most life-threatening chemotherapy-associated toxicities. A 66 years old woman came to an emergency department of a secondary healthcare facility one week after her final chemotherapy with dose regimen of docetaxel and epirubicin, followed by having nausea, vomitus, and general fatigue with a fever of 38.2°C. Based on her medical record, she had experienced breast malignancy for almost two years and had already conducted mastectomy three months after her diagnosis. Her leukocyte number was only 300 cells per mm3, with 23% neutrophil, hypoalbuminemia, and hypokalaemia. She was then treated in an internal ward and was given intravenous ceftazidime, fluid, granulocyte colony-stimulating factor, albumin transfusion, intravenous potassium replacement, and symptomatic medication. After two days of inpatient care, she was referred to an oncology team in a tertiary healthcare facility. Febrile neutropenia is considered as a fever with a low neutrophil number as a result of bone marrow suppression. The neutrophil plays an essential role as the body’s first line of defence. This condition could make the patient more vulnerable to infections. The Patient was given broad-spectrum antibiotics and typically hospitalized to allow close monitoring until the neutropenia was  resolved. Febrile neutropenia possesses a serious threat to patients with breast malignancy who are on cytotoxic chemotherapy. Urgent full blood count and immediate broad-spectrum antibiotic administration are significant to reduce morbidity and mortality.

Keywords

febrile neutropenia chemotherapy-associated breast malignancy

Article Details

License

Authors who publish in the Jurnal Kedokteran dan Kesehatan Indonesia agree to the following terms:

  1. Authors retain copyright and grant Jurnal Kedokteran dan Kesehatan Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution Licence that allows others to adapt (remix, transform, and build) upon the work non-commercially with an acknowledgement of the work's authorship and initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
  2. Authors are permitted to share (copy and redistribute) the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in Jurnal Kedokteran dan Kesehatan Indonesia.
How to Cite
Wibisono, E. A., & Wiliyanto, O. (2020). Adjuvant chemotherapy-associated febrile neutropenia in a patient with breast malignancy: A case report. JKKI : Jurnal Kedokteran Dan Kesehatan Indonesia, 11(2), 214–218. https://doi.org/10.20885/JKKI.Vol11.Iss2.art15
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Kar M, Rakesh R. Indian guidelines for febrile neutropenia. 2002;3–6.
  2. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Annals of Oncology. 2016;27(Supplement 5):v111–8.
  3. Wang Z, Chen JQ, Liu JL, Qin XG. Serious neutropenia following neoadjuvant chemotherapy for locally advanced breast cancer: A case report. Oncology Letters. 2016;11(2):1597–9.
  4. Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015;26(10):1054–60.
  5. Mugada V, Ramineni H, Padala D. 5-Fluorouracil induced severe febrile neutropenia and death. Journal of Young Pharmacists. 2017;9(1):133–4.
  6. Nayak BSK. Case report: Febrile neutropenia in a patient with carcinoma of larynx. Journal of Medical Science And clinical Research. 2018;6(11):325–7.
  7. Cameron D. Management of chemotherapy-associated febrile neutropenia. British Journal of Cancer . 2009;101(S1):S18–22.
  8. Patel K, West H. Febrile neutropenia. JAMA Oncology. 2017;3(12):1751.
  9. Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: Guidelines of the infectious diseases working party (AGIHO) of the German society of hematology and medical oncology (DGHO). Annals of Hematology. 2017;96(11):1775–92.
  10. Naik JD, Sathiyaseelan SRK, Vasudev NS. Easily missed?: Febrile neutropenia. The British Medical Journal. 2011;342(7788):103.
  11. Hirano A, Shimizu T, Watanabe O, Kinoshita J, Kimura K, Kamimura M, et al. Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer. Anticancer Research. 2008;28(6 B):4137–42.
  12. Vidal L, Ben dor I, Paul M, Eliakim-Raz N, Pokroy E, Soares-Weiser K, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database Systematic Review. 2013;2013(10).
  13. Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: Systematic review and meta-analysis. BMC Cancer. 2011;11.
  14. Bennett CL, Djulbegovic B, Norris LAB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. The New England Journal of Medicine. 2013;368(12):1131–9.
  15. Mhaskar R, Clark OAC, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Systematic Review. 2014;2014(10).
  16. .